Quetiapine: 5 agencies, 1999–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 18.9 years separate the first record, 1 Aug 1999 at PHARMAC (New Zealand), from the most recent, 2018 at PBAC (Australia).
AWMSG (Wales) changed its position: recommended on 15 Sep 2009, not recommended by 13 Oct 2011.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for quetiapine, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2018; on this evidence the file is dormant.
Against its own class, quetiapine is an outlier: 62% of its decisive outcomes were positive, where molecules sharing ATC class N05A average 85%.
5 distinct indication wordings are recorded for quetiapine by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 13 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess quetiapine, on 1 Aug 1999; PBAC (Australia) did not open a file until 2018 — an unusually long tail of 18.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
4 of the 5 agencies here assessed quetiapine more than once, AWMSG (Wales) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed quetiapine.
The full ledger for quetiapine reads 5 recommended, 3 other, 3 not recommended and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2018 | Schizophrenia, acute mania and bipolar I disorder | PBAC recommended that the current listing for the 25 mg strength quetiapine tablets be cha… | source |
| HAS (France) | 30 Nov 2011 | Re-assessment of SMR and ASMR | ASMR V | source |
| AWMSG (Wales) | 13 Oct 2011 | For the treatment of major depressive episodes in bipolar disorder. | not endorsed (non-submission) | source |
| SMC (Scotland) | 10 Oct 2011 | Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) | not recommended | source |
| PHARMAC (New Zealand) | 1 Feb 2004 | Mania associated with Bipolar disorder | PTAC advice: No Formal Recommendation · decision reached | source |
8 further decisions for quetiapine, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- asenapine — divergent outcome (recommended vs not recommended) on a shared indication
- aripiprazole — same ATC class N05A — Psycholeptics
- risperidone — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
Coverage: 13 decisions for quetiapine from 5 agencies, 1999 to 2018. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.